$CNVI.V $CNVIF #TCT2026 is almost here, and as CEO @ThomasLooby shared: “This year’s TCT marks an important step for Conavi as we showcase our next-generation system following FDA clearance, giving physicians IVUS and OCT imaging simultaneously in a single pullback… We look forward to introducing physicians to our cleared system and building relationships with potential clinical users as we advance our U.S. commercialization.” See below for where you can connect with #CNVI and come by our booth 📍 4026 in the Main Aisle! More details on @TCTConference here 🔗 lnkd.in/g5Tu2U3f

$CNVI.V $CNVIF Every step taken toward clearer insights helps to save lives. At #Conavi, that is what drives us. 🫀 This #WorldHeartDay, we stand with the @worldheartfed in support of #DontMissABeat, a global push for greater awareness, early detection, and timely action when it comes to #HeartHealth. 🩺 Cardiovascular disease remains the world’s leading cause of death, making every diagnostic insight and treatment decision critical.

$CNVI.V $CNVIF Two imaging modalities, complementary insights to guide clinical decisions. 🩺 A @ccijournal case report shows the value of #Conavi's hybrid imaging system during a complex coronary procedure, allowing physicians to use: ➡️ #IVUS: vessel sizing and plaque assessment ➡️ #OCT: higher resolution to characterize the extent and depth of the dissections ➡️ Together: helped physicians identify proximal and distal edge dissections, as well as white thrombus, following stent placement 🔗 lnkd.in/gxH6uaqp

$CNVI.V $CNVIF #Conavi is pleased to share a new peer-reviewed case report published in Catheterization and Cardiovascular Interventions, demonstrating the clinical utility of our hybrid #IVUS-#OCT system. We also announced that Aman Thind, Co-Founder and CTO, is taking on leadership of R&D. #CNVI Press Release 🔗 lnkd.in/g5e-x5s7 @ccijournal publication 📋 lnkd.in/gxH6uaqp

$CNVI.V $CNVIF #Conavi is pleased to announce the successful closing of its $10 million public offering! Thank you to Bloom Burton and the syndicate of agents for leading this transaction, as well as our new and existing investors for the strong support and confidence in #CNVI as we advance this next stage of our growth. Full Press Release 🔗 lnkd.in/grMVGdEb

$CNVI.V $CNVIF @SCAI New publication in @MyJSCAI titled “Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules,” demonstrates how complementary #IVUS and #OCT information supports lesion assessment, treatment planning, and stent optimization while helping manage contrast use. Following recent U.S. FDA #510k clearance, this publication featuring #Conavi's hybrid system further strengthens the clinical evidence supporting our upcoming commercial rollout. 🔗 Full Release: lnkd.in/gt-CwHds 🔗 Publication: lnkd.in/gMr_CJT5

$CNVI.V $CNVIF This quarter, #Conavi received the 'Best New Technology Solution– Imaging' Award for its next-generation hybrid #IVUS-#OCT imaging platform. 🫀 Thank you @MedTech_Awards for this recognition! More details 🔗 medtechbreakthrough.com/2026… #MedTech #IntravascularImaging #HealthcareInnovation

New @MyJSCAI publication analyzed 25 studies across multiple countries... When evaluated over a patient’s lifetime, #IntravascularImaging not only improves outcomes significantly, but is cost-effective and often cost-saving, reducing adverse events and repeat interventions. Increases number of #PCI procedures, clinical evidence, guideline support, and adoption of IVI, understanding its long-term economic impact has become increasingly important. Read more on the publication here 🔗 lnkd.in/etsiwkGD $CNVI.V $CNVIF @SCAI #Conavi

$CNVI.V $CNVIF From CEO @ThomasLooby: "Fiscal Q2 2026 marked a transformational period for #Conavi highlighted by FDA #510k clearance of our next-generation hybrid #IVUS-#OCT imaging system, a milestone that positions the Company for commercial launch in the U.S..." Read more 🔗 lnkd.in/ecbEGaVP

$CNVI.V $CNVIF #Conavi CEO @ThomasLooby sat down with @RadiusResearch to discuss everything surrounding our next-generation imaging system and recent U.S. #FDA 510(k) clearance! ☑️ Watch the full video here 🔗 lnkd.in/e2NaZZF4 #CNVI #IntravascularImaging #510k #CEOInterview

$CNVI.V $CNVIF ▶️ In case you missed it: #TBT to the #BBHIC2026 last week! 1st #Conavi presentation after receiving U.S. FDA #510k clearance on our next-generation hybrid imaging system. 🔗 Watch it here: lnkd.in/er6QQMfi

$CNVI.V $CNVIF Exciting week! 🫀 ☑️U.S. FDA #510k Clearance ☑️ Productive time at #BBHIC2026 ☑️#TagAward Recipient 🔗 lnkd.in/eN6CNmQB As #Conavi CEO Tom Looby expressed: "We are honoured to receive this recognition from TAG at such an important moment for Conavi, this award reflects the strength of our technology and the dedication of our team. With the recent FDA clearance of our next-generation hybrid intravascular imaging system, we are entering a new phase focused on U.S. commercialization and delivering meaningful clinical impact."

$CNVI.V $CNVIF #Conavi is thrilled to announce FDA #510k clearance of our next-generation hybrid imaging system and to begin executing on our U.S. commercial launch for H2 2026. As the first co-registered, co-aligned #IVUS and #OCT platform, our system helps give physicians a more complete view of the vessel, streamline workflows, and enhance precision across one of the most common procedures globally. With clinical evidence and guideline support strengthening, this represents a significant opportunity in the rapidly expanding #IntravascularImaging market. Thank you to the #CNVI team, partners, physicians, and investors who made this possible! 🫀🌏 Full Release 🔗 lnkd.in/eHkJgdd7

$CNVI.V $CNVIF CEO @ThomasLooby will be presenting and available for 1-on-1 meetings at the the 2026 Bloom Burton & Co. Healthcare Investor Conference. #Conavi Presentation Details: 📆 Wednesday April 22 🕥 9:30 a.m. ET 📍 Metro Toronto Convention Centre ▶️ Webcast: lnkd.in/er6QQMfi 🔗 More Information: lnkd.in/eDVJWWGY #BBHIC26

$CNVI $CNVIF On #WorldHealthDay, we join @WHO to #StandWithScience! 🧡🌎 Behind the 4M+ #PCI's performed each year, is a parent, spouse, friend, and a physician turning evidence into action to save lives. #Conavi believes powerful health decisions start with clarity and advance without compromise. This is why we’re combining #IVUS with #OCT to remove potential blind spots with single modality #IntravascularImaging systems. 🩺

$CNVI.V $CNVIF It’s the season for springing into our next-gen imaging! 🌱 On the Empowered Patient Podcast, #Conavi CEO @ThomasLooby discussed how we're leveraging #AI in our #hybridimaging to drive stronger algorithms, automated insights, and less guesswork for cardiologists. 🫀 Listen here 🎧 lnkd.in/eRUthCfT

$CNVI.V $CNVIF A @EuroInterventio analysis of 350,000+ coronary procedures in Japan’s National Database, shows how imaging-guided PCI is: ➡️ Delivering significantly better outcomes for ACS patients ➡️ Driving a fundamental shift in how interventions are performed ➡️ Demonstrating how #IVUS & #OCT reveals what the other cannot Providing physicians with the ability to leverage strengths of both modalities during the same procedure is what #ConaviMedical feels is an important step forward in #InterventionalCardiology. 🫀 Details 🔗 lnkd.in/dvBjPDCD

$CNVI.V $CNVIF Another validating quarter for #Conavi! $12M in funding secured and another publication reinforcing the advantages of hybrid #IVUS + #OCT imaging. We’re advancing the next-generation #Novasight toward commercialization with confidence and are on track to initiate the targeted U.S. launch in Q3 2026. Full update 🔗 lnkd.in/gvQufPUj